Company news

Daiichi Sankyo Company, Limited (TSE:4568) news

Daiichi Sankyo Company, Limited news releases on 6ix. Latest, Oct 2, 2026: Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit…

Daiichi Sankyo Company, Limited (TSE:4568) news

Press releases & updates

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Notice Regarding NTK’s Filing of Appeal in Damages Claim Against Daiichi Sankyo

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Daiichi Sankyo : Receives Favorable Judgment in Damage Claim Filed by NTK

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

(Modification of Disclosed Matter) Notice Regarding Change in the Effective Date of the Absorption-type Merger of Daiichi Sankyo with Its Wholly Owned

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

(Re-correction) "Reference Data for FY2025 Consolidated Financial Results"

(Correction) Partial Correction of "Financial Results for the Fiscal Year Ended March 31, 2026 [IFRS] (Consolidated)"

Enhertu(R) Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Own Shares as Restricted Share-Based Compensation

Daiichi Sankyo Announces Disposal of Own Shares as Medium-Term Performance-Based Share Compensation for Company’s Directors and Corporate Officers

Daiichi Sankyo - Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Daiichi Sankyo Europe Pfaffenhofen Plant (Germany) has obtained ISO45001:2018 certification

Daiichi Sankyo Announces Disposal of Own Shares as Restricted Share-Based Compensation

Daiichi Sankyo : Consolidated Financial Statements and Independent Auditor's Report for FY2025PDF

Notice Regarding the Conclusion of a Money Loan Agreement with Financial Covenants

Daiichi Sankyo : Vanflyta® Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Positive AML

Daiichi Sankyo : Selected as SX Brand for the Third Consecutive Year

Daiichi Sankyo Concludes pCPA Letter of Intent for Vanflyta® in Newly Diagnosed FLT3-ITD Positive AML

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Daiichi Sankyo : Participation in WHO-GBCI Phase 2 through a Partnership with City Cancer Challenge (C/Can) — Contributing to Breast Cancer Care in Low- and Middle-Income Countries

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Daiichi Sankyo : Announces Occurrence of Losses Related to Review of Product Supply Plans and Revision of Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026

Daiichi Sankyo Announces Rescheduling of the Announcement of Consolidated Financial Results for Year Ended March 31, 2026

Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies

Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase

4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program

Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms

Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.

SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology